Commentary on King-Kallimanis et al.: Inadequate measurement of symptomatic adverse events in immunotherapy registration trials

Abstract

Get full access to this article

View all access options for this article.

References

Atkinson

Wagner

Basch

Trustworthiness of patient-reported outcomes in unblinded cancer clinical trials. JAMA Oncol 2017; 3(6): 738–739.

Kluetz

O’Connor

Soltys

Incorporating the patient experience into regulatory decision making in the USA, Europe, and Canada. Lancet Oncol 2018; 19(5): e267–e274.

King-Kallismanis

Howie

Roydhouse

et al . Patient reported outcomes in Anti-PD-1/PD-L1 inhibitor immunotherapy registration trials: FDA analysis of data submitted and future directions. Clin Trials 2019; 16(3) 322–326.

Basch

Rogak

Dueck

AC.

Methods for implementing and reporting patient-reported outcome (PRO) measures of symptomatic adverse events in cancer clinical trials. Clin Ther 2016; 38(4): 821–830.

Trask

Dueck

Piault

et al . Patient-reported outcomes version of the common terminology criteria for adverse events: methods for item selection in industry-sponsored oncology clinical trials. Clin Trials 2018; 15(6): 616–623.

DeMuro

Clark

Doward

et al . Assessment of PRO label claims granted by the FDA as compared to the EMA (2006-2010). Value Health 2013; 16(8): 1150–1155.

21st Century Cures Act. 2016, https://www.congress.gov/bill/114th-congress/house-bill/34/ (accessed 7 February 2019).

Roydhouse

King-Kallimanis

Howie

et al . Blinding and patient-reported outcome completion rates in US food and drug administration cancer trial submissions, 2007-2017. J Natl Cancer Inst. Epub ahead of print 17 December 2018. DOI: 10.1093/jnci/djy181.

Basch

High compliance rates with patient-reported outcomes in oncology trials submitted to the US food and drug administration. J Natl Cancer Inst. Epub ahead of print 17 December 2018. DOI: 10.1093/jnci/djy183.